scispace - formally typeset
Open AccessJournal ArticleDOI

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments.

Shin Jie Yong
- 01 Jan 2021 - 
- Vol. 53, Iss: 10, pp 737-754
Reads0
Chats0
TLDR
In this paper, a review of the literature on long COVID-19 syndrome is presented, which is driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (i.e. from viral persistence, immune dysregulation, and autoimmunity).
Abstract
Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and later in scientific and medical communities. This illness is poorly understood as it affects COVID-19 survivors at all levels of disease severity, even younger adults, children, and those not hospitalized. While the precise definition of long COVID may be lacking, the most common symptoms reported in many studies are fatigue and dyspnoea that last for months after acute COVID-19. Other persistent symptoms may include cognitive and mental impairments, chest and joint pains, palpitations, myalgia, smell and taste dysfunctions, cough, headache, and gastrointestinal and cardiac issues. Presently, there is limited literature discussing the possible pathophysiology, risk factors, and treatments in long COVID, which the current review aims to address. In brief, long COVID may be driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (e.g. from viral persistence, immune dysregulation, and autoimmunity). The associated risk factors may include female sex, more than five early symptoms, early dyspnoea, prior psychiatric disorders, and specific biomarkers (e.g. D-dimer, CRP, and lymphocyte count), although more research is required to substantiate such risk factors. While preliminary evidence suggests that personalized rehabilitation training may help certain long COVID cases, therapeutic drugs repurposed from other similar conditions, such as myalgic encephalomyelitis or chronic fatigue syndrome, postural orthostatic tachycardia syndrome, and mast cell activation syndrome, also hold potential. In sum, this review hopes to provide the current understanding of what is known about long COVID.

read more

Citations
More filters
Journal ArticleDOI

Editorial for “Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form”

Arad Dotan, +1 more
- 20 Jan 2023 - 
TL;DR: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019, and has infected numerous subjects worldwide as discussed by the authors , and has been shown to be contagious.
Journal ArticleDOI

Diagnostic features of multiple organic system disorders associated with COVID-19 in a child of primary school age

TL;DR: In this paper , the authors presented a diagnostically complex clinical case describing the development of multiple organ damage in a 7-year-old child after contact with a mother who was sick with COVID-19.
Journal ArticleDOI

Leveraging on Rehabilitation in Long Covid Management

TL;DR: The cardiopulmonary, neurological and musculoskeletal presentations in Long COVID makes leveraging on rehabilitation in its management inevitable, and long term effects of COVID-19 (Long COVID) was recognized in 2020 summer.
Journal ArticleDOI

Validation of the Slovakian Version of the “Post‑acute (Long) COVID‑19 Quality of Life Instrument” and Pilot Study

TL;DR: The PAC-19QoL instrument was translated into the Slovakian language and administrated to patients with post COVID-19 syndrome as discussed by the authors , and the internal consistency of the instrument was evaluated by using Pearson's correlation coefficient and Spearman's rank correlation.
Posted ContentDOI

Symptoms and Quality of Life Characteristics of Family Therapy Patients Infected with Omicron in China ——a Retrospective Observational Study

TL;DR: Wang et al. as mentioned in this paper conducted a survey of 732 Chinese residents and screened 526 patients who had been infected with omicron and conducted a retrospective survey of symptoms and quality of life in these patients.
References
More filters
Journal ArticleDOI

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

TL;DR: During the epidemic period of COVID-19, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.
Journal ArticleDOI

The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study

TL;DR: A conceptual framework and a set of research guidelines for use in studies of the chronic fatigue syndrome are developed that cover the clinical and laboratory evaluation of persons with unexplained fatigue; the identification of underlying conditions that may explain the presence of chronic fatigue; revised criteria for defining cases of the Chronic fatigue syndrome; and a strategy for dividing the chronic Fatigue syndrome and other unexplained cases of Chronic fatigue into subgroups.
Journal ArticleDOI

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

TL;DR: In this small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection.
Journal ArticleDOI

Role of the Microbiota in Immunity and Inflammation

TL;DR: In high-income countries, overuse of antibiotics, changes in diet, and elimination of constitutive partners, such as nematodes, may have selected for a microbiota that lack the resilience and diversity required to establish balanced immune responses.
Journal ArticleDOI

Persistent Symptoms in Patients After Acute COVID-19.

TL;DR: This case series describes COVID-19 symptoms persisting a mean of 60 days after onset among Italian patients previously discharged from CO VID-19 hospitalization.
Related Papers (5)
Trending Questions (1)
What are the most effective treatments for long COVID?

The paper mentions that personalized rehabilitation training and therapeutic drugs repurposed from similar conditions hold potential as treatments for long COVID. However, it does not provide specific information on the most effective treatments.